The global genomic biomarker market size was exhibited at USD 4.84 billion in 2022 and it is expected to hold around USD 8.6 billion by 2030, growing at a CAGR of 7.46% from 2022 to 2030.
The global genomic biomarker market size was exhibited at USD 4.84 billion in 2022 and it is expected to hold around USD 8.6 billion by 2030, growing at a CAGR of 7.46% from 2022 to 2030.
Genomic biomarkers are traits of DNA and RNA that are used as diagnostic indicators, disease characterization tools, and therapy selection tools. The body’s response to treatment or other treatments, as well as pathological and physiological processes, are all represented by it. The healthcare industry’s expanded usage of novel pharmaceuticals, greater R&D initiatives to identify chronic disorders, and expanding use of less invasive procedures are all having a positive effect on the market for genetic biomarkers.
Along with positive government initiatives connected to genetic research, the growing emphasis on the availability of personalized medicine for enabling improved patient care is enhancing the growth prognosis for the global market. When it comes to identifying and diagnosing COVID-19 disease, biomarkers are crucial.
Get the Sample Copy of This Report@ https://www.precedenceresearch.com/sample/2231
Market Growth
The market situation has increased due to ongoing improvements in laboratory tests and genetic technology. The incidence of ovarian cancer is on the rise, and the use of genetic biomarkers in medicine is also on the rise, and these are major aspects that are propelling the global market. According to the Alzheimer’s Association, 5.8 million Americans over 50 are anticipated to have Alzheimer’s dementia in 2019, and 14 million are anticipated to have it by the year 2050. Due to the growing number of people suffering from neurological illnesses, there is an urgent need for genetic biomarkers that could promote market expansion on a global scale.
Medical practice is increasingly relying on companion diagnostics and biomarkers, which ultimately leads to more disease-specific diagnosis, treatment, and intense care. As a result, the demand for genetic biomarkers has grown significantly from both pharmaceutical companies and healthcare providers, which has a significant impact on the expansion of the global market. The growing demand for genetic biomarkers in prostate cancer is another factor that is projected to favorably impact market growth.
Genomic Biomarker Market Report Scope
| Report Coverage | Details |
| Market Size In 2022 | USD 4.84 Billion |
| Market Size By 2030 | USD 8.6 Billion |
| Growth Rate From 2022 to 2030 | CAGR of 7.46% |
| Base Year | 2022 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | By Type, By Disease Indication, By End-User |
| Companies Mentioned | Almac Group, Cancer Genetics Inc, Eurofins Scientific, Thermo Fisher Scientific Inc, Aepodia SA, Epigenomics AG, US Biomarkers Inc., Roche Diagnostics, Myriad Genetics, Bio-Rad Laboratories |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Regional Analysis
Geographically, North America dominated the world market in 2020 and is anticipated to keep doing so going forward due to the region’s increased emphasis on healthcare and life science research, as well as the expanding use of genomic biomarkers for illness early diagnosis. The GenomeAsia 100K Effort sequencing (WGS) project, for instance, makes genetic discoveries possible throughout the Asian economy. The study includes several Asian countries, including South Korea, Malaysia, India, Indonesia, and others in order to capture the widest range of genetic variation. This is expected to contribute to the future growth of the global biomarkers market.
Ask Here for Customization@ https://www.precedenceresearch.com/customization/2231
Market Dynamics
Drivers
A number of factors, including an increase in the development of clinical laboratory tests, technological advancement, and an increase in the incidence of ovarian and gastric cancer, the demand for genomic biomarker-based medicine, and the burden of chronic diseases, are driving the market for genomic biomarkers. The coronavirus pandemic had an impact on various organizations involved in the global healthcare business as well as the design, production, and distribution of healthcare products. The demand for genetic biomarkers rises in pandemic situations as a result of the development and approval of novel, innovative medications and biological products. The increased incidences of cardiovascular diseases, rheumatoid arthritis, and neurological disorders connected to COVID-19 infection are expected to have a beneficial impact on the market growth for genetic biomarkers, though, as they are crucial for the identification of such diseases.
Restraints
Several issues with the use and analysis of genetic biomarkers are anticipated to hamper market expansion throughout the course of the projected period. According to an article released by the Intestinal Journal in November 2019, some genomic biomarkers, such as miRNA found in stool samples, cannot be used as a stand-alone diagnostic tool for the detection of colon cancer due to worries about the biomarker’s stability and the inability to establish an adequate predictive value for the diagnosis of colon cancer.
Opportunities
The market for genomic biomarkers is being driven by a number of factors, including the rise in cases of ovarian and gastric cancer, the demand for genomic biomarker-based medicine, and the burden of chronic diseases. Technological advancement and development in clinical laboratory tests are also important factors that are accelerating market growth. Additionally, the market for genetic biomarkers will experience growth due to modernization and technical developments in the healthcare industry as well as increased demand from developing nations.
Type Insights
The genetic biomarkers are divided into prognostic and predictive biomarkers based on their nature. Protein markers, or biomarkers, aid in the diagnosis of a number of diseases, including cardiovascular conditions. These protein markers are used to identify cells’ antigen-releasing molecules, which in turn cause an immunological response when they come into contact with circulating antibodies.
Prognostic biomarkers can be used to monitor the progress of cancer treatment, identify the stage and potential malignancy of the tumor, and forecast the chance of disease remission in each unique case. Chronic disease relapses and recurrences are common in patients due to poor lifestyle choices, genetic makeup, family history, and other reasons.
Disease Indication Insights
The genetic biomarkers are divided into oncology, neurological diseases, cardiovascular diseases, renal disorders, and other categories based on the disease indication. According to the World Health Organization, cancer is the second-leading cause of death globally, and it accounts for 70% of deaths in low- and middle-income countries (WHO). Additionally, 9.6 million cancer-related fatalities and 18.1 million new cases were reported globally in 2018, according to the WHO.
The rise in the prevalence of cardiovascular disease and the outstanding application of genomic biomarkers in ischemic heart illnesses are two aspects that are influencing the market demand for genomic biomarkers. The increasing prevalence of CVD directly affects the demand for genetic biomarkers by expanding access to reliable, high-quality medical treatments.
End-User Insights
Hospitals, diagnostic centers, and other facilities are divided up into segments based on the end user of the genetic biomarkers. Using genetic indicators to quickly and precisely diagnose a variety of illnesses, such as cancer, infectious infections, neurological abnormalities, and cardiovascular issues. It is projected that the hospital sector will grow much more quickly than the overall market over the projection period. The market is anticipated to grow as a consequence of factors such as the growing availability of genetic biomarkers in hospitals, increased healthcare spending by the government, and numerous hospital initiatives that treat chronic diseases.
Related Reports
Healthcare Software As A Service Market 2022 To 2030
https://www.precedenceresearch.com/healthcare-software-as-a-service-market
Next Generation Surgical Robotics Market 2022 To 2030
https://www.precedenceresearch.com/next-generation-surgical-robotics-market
Augmented and Virtual Reality in Healthcare Market 2022 To 2030
https://www.precedenceresearch.com/augmented-and-virtual-reality-in-healthcare-market
Recent Development
- In August 2022, The FDA approved InRoche’s companion diagnostic to help doctors determine which patients with dMMR solid tumors are candidates for anti-PD-1 immunotherapy.
- In August 2022, In order to better serve the medical diagnostic and healthcare sectors, Bio-Rad acquires Curiosity Diagnostics for a maximum total cost of $170 million, which will be made up of about $100 million in cash and up to $70 million in potential future milestone payments.
- In August 2022, Myriad Genetics expanded its coverage in Japan for the use of the BRACAnalysis® Diagnostic System as a companion diagnostic to Lynparza® in early-stage breast cancer.
- In June 2022, according to the National Cancer Institute, treating precancerous anal lesions significantly lowers the risk of developing anal cancer in those living with HIV.
Major Key Players
Almac Group, Cancer Genetics Inc, Eurofins Scientific, Thermo Fisher Scientific Inc, Aepodia SA, Epigenomics AG, US Biomarkers Inc., Roche Diagnostics, Myriad Genetics, Bio-Rad Laboratories
Market Segmentation
By Type
- Predictive Biomarkers
- Prognostic Biomarkers
By Disease Indication
- Oncology
- Cardiovascular Diseases
- Neurological Diseases
- Renal Disorders
- Others
By End-User
- Hospitals
- Diagnostic Centers
- Others
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
https://www.precedenceresearch.com/table-of-content/2062
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/2231
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333